Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.
Anna MorraMaartje A C SchreursIrene L AndrulisHoda Anton-CulverAnnelie AugustinssonMatthias W BeckmannSabine BehrensStig E BojesenManjeet K BollaHiltrud BrauchAnnegien BroeksSaundra S BuysNicola J CampJose E CastelaoMelissa H CessnaJenny Chang-ClaudeWendy K Chungnull nullSarah V ColonnaFergus J CouchAngela CoxSimon S CrossKamila CzeneMary B DalyJoe DennisPeter DevileeThilo DörkAlison M DunningMiriam DwekDouglas F EastonDiana M EcclesMikael ErikssonD Gareth EvansPeter A FaschingTanja N FehmJonine D FigueroaHenrik FlygerMarike GabrielssonManuela Gago-DominquezMontserrat García-ClosasJosé Angel García-SaenzJeanine GenkingerFelix GrassmannMelanie GündertEric HahnenChristopher A HaimanUte HamannPatricia A HarringtonJaana M HartikainenReiner HoppeJohn L HopperRichard S HoulstonAnthony Howellnull nullnull nullAnna JakubowskaWolfgang JanniHelena JernströmIsabelle DurotNichola JohnsonMichael E JonesVessela N KristensenAllison W KurianDiether LambrechtsLoic Le MarchandAnnika LindblomJan LubińskiMichael P LuxArto MannermaaDimitrios MavroudisAnna Marie MulliganTaru A MuranenHeli NevanlinnaInes NevelsteenPatrick NevenWilliam G NewmanNadia ObiKenneth OffitAndrew F OlshanTjoung-Won Park-SimonAlpa V PatelPaolo PeterlongoKelly-Anne PhillipsDijana Plaseska-KaranfilskaEric C PolleyNadege PresneauKatri PylkäsBrigitte RackPaolo RadiceMuhammad Usman RashidValerie RheniusMark RobsonAtocha RomeroEmmanouil SaloustrosElinor J SawyerRita K SchmutzlerSabine SchuetzeChristopher ScottMitul ShahSnezhana SmichkoskaMelissa C SoutheyWilliam J TapperLauren R TerasRob A E M TollenaarKatarzyna TomczykIan TomlinsonMelissa A TroesterCeline M VachonElke M van VeenQin WangCamilla WendtHans WildiersRobert WinqvistArgyrios ZiogasPer HallPaul D P PharoahMuriel A AdankAntoinette HollestelleMarjanka K SchmidtMaartje J HooningPublished in: Cancer medicine (2023)
Systemic therapy was associated with reduced CBC risk irrespective of CHEK2 c.1100delC status. Moreover, CHEK2 c.1100delC carriers had shorter BCSS, which appears not to be fully explained by their CBC risk.